TrialSignal transduction and targeted therapy2026

HILL: the efficacy and safety of hepatic arterial infusion chemotherapy with the FOLFOX regimen combined with lenvatinib and the PD-L1 inhibitor durvalumab in unresectable hepatocellular carcinoma: a prospective, single-arm, phase 2 clinical trial.

Shao-Hua Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.